Cargando…
Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai
OBJECTIVES: To characterize the pattern of approved anti-vascular endothelial growth factor (VEGF) treatments among patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in the United Arab Emirates (UAE). METHOD: This was a retrospective, nonrandomized, o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277020/ https://www.ncbi.nlm.nih.gov/pubmed/34255798 http://dx.doi.org/10.1371/journal.pone.0254569 |
_version_ | 1783722001188257792 |
---|---|
author | Kozak, Igor Gurbaxani, Avinash Safar, Ammar Rao, Prasan Masalmeh, Amal Assaf, Hazar Farghaly, Mohamed Pathak, Prathamesh Natarajan, Ashok Saffar, Insaf |
author_facet | Kozak, Igor Gurbaxani, Avinash Safar, Ammar Rao, Prasan Masalmeh, Amal Assaf, Hazar Farghaly, Mohamed Pathak, Prathamesh Natarajan, Ashok Saffar, Insaf |
author_sort | Kozak, Igor |
collection | PubMed |
description | OBJECTIVES: To characterize the pattern of approved anti-vascular endothelial growth factor (VEGF) treatments among patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in the United Arab Emirates (UAE). METHOD: This was a retrospective, nonrandomized, observational cohort analysis of the Dubai Real-world Claims Database with a 360-day follow-up period. Adult patients diagnosed with nAMD or DME treated with ranibizumab or aflibercept for the first time were included. The primary objective was to evaluate anti-VEGF treatment patterns with respect to the proportion of patients receiving ranibizumab and aflibercept for nAMD and DME separately. RESULTS: Of the 451 patients included in the final study cohort, 83.6% and 16.4% had a diagnosis of DME (ranibizumab: 48.5%; aflibercept: 51.5%) and nAMD (ranibizumab: 40.5%; aflibercept: 59.5%), respectively, at baseline. Treatment frequency of ranibizumab/aflibercept was similar for nAMD (mean: 2.4/2.9 injections; p = 0.2389) with fewer injections in the ranibizumab cohort for DME (mean: 1.9/2.5 injections; p = 0.0002). Most patients received ≤3 anti-VEGF injections during the 360-day follow-up period. The time between consecutive treatments was large (nAMD: 73.6 days/10.5 weeks; DME: 80.5 days/11.5 weeks). Approximately 10%–13.5% of patients switched their anti-VEGF therapy. Most patients (83.8%) had a diabetes diagnosis during the follow-up period. CONCLUSIONS: This real-world study provides an initial understanding of anti-VEGF treatment patterns in patients with nAMD and DME in the UAE. Treatment frequency of the 2 anti-VEGF agents assessed was similar in both patient populations. Both treatments were infrequently administered with large dosing intervals. |
format | Online Article Text |
id | pubmed-8277020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-82770202021-07-20 Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai Kozak, Igor Gurbaxani, Avinash Safar, Ammar Rao, Prasan Masalmeh, Amal Assaf, Hazar Farghaly, Mohamed Pathak, Prathamesh Natarajan, Ashok Saffar, Insaf PLoS One Research Article OBJECTIVES: To characterize the pattern of approved anti-vascular endothelial growth factor (VEGF) treatments among patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in the United Arab Emirates (UAE). METHOD: This was a retrospective, nonrandomized, observational cohort analysis of the Dubai Real-world Claims Database with a 360-day follow-up period. Adult patients diagnosed with nAMD or DME treated with ranibizumab or aflibercept for the first time were included. The primary objective was to evaluate anti-VEGF treatment patterns with respect to the proportion of patients receiving ranibizumab and aflibercept for nAMD and DME separately. RESULTS: Of the 451 patients included in the final study cohort, 83.6% and 16.4% had a diagnosis of DME (ranibizumab: 48.5%; aflibercept: 51.5%) and nAMD (ranibizumab: 40.5%; aflibercept: 59.5%), respectively, at baseline. Treatment frequency of ranibizumab/aflibercept was similar for nAMD (mean: 2.4/2.9 injections; p = 0.2389) with fewer injections in the ranibizumab cohort for DME (mean: 1.9/2.5 injections; p = 0.0002). Most patients received ≤3 anti-VEGF injections during the 360-day follow-up period. The time between consecutive treatments was large (nAMD: 73.6 days/10.5 weeks; DME: 80.5 days/11.5 weeks). Approximately 10%–13.5% of patients switched their anti-VEGF therapy. Most patients (83.8%) had a diabetes diagnosis during the follow-up period. CONCLUSIONS: This real-world study provides an initial understanding of anti-VEGF treatment patterns in patients with nAMD and DME in the UAE. Treatment frequency of the 2 anti-VEGF agents assessed was similar in both patient populations. Both treatments were infrequently administered with large dosing intervals. Public Library of Science 2021-07-13 /pmc/articles/PMC8277020/ /pubmed/34255798 http://dx.doi.org/10.1371/journal.pone.0254569 Text en © 2021 Kozak et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kozak, Igor Gurbaxani, Avinash Safar, Ammar Rao, Prasan Masalmeh, Amal Assaf, Hazar Farghaly, Mohamed Pathak, Prathamesh Natarajan, Ashok Saffar, Insaf Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai |
title | Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai |
title_full | Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai |
title_fullStr | Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai |
title_full_unstemmed | Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai |
title_short | Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai |
title_sort | treatment patterns in patients with age-related macular degeneration and diabetic macular edema: a real-world claims analysis in dubai |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277020/ https://www.ncbi.nlm.nih.gov/pubmed/34255798 http://dx.doi.org/10.1371/journal.pone.0254569 |
work_keys_str_mv | AT kozakigor treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT gurbaxaniavinash treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT safarammar treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT raoprasan treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT masalmehamal treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT assafhazar treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT farghalymohamed treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT pathakprathamesh treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT natarajanashok treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai AT saffarinsaf treatmentpatternsinpatientswithagerelatedmaculardegenerationanddiabeticmacularedemaarealworldclaimsanalysisindubai |